BioSpace News Archive

Eisai Inc. announced new effectiveness and safety data from the Phase 3 clinical development program for lemborexant, an investigational agent for sleep-wake regulation, which is currently being studied for the treatment of insomnia, a sleep-wake disorder, and for Irregular Sleep-Wake Rhythm Disorder (ISWRD) in patients with Alzheimer’s disease (AD) dementia.

Top Journal Award in the Field of Plasma Physics Awarded for Research in Particle Acceleration in Magnetic Reconnection

RH Nanopharmaceuticals, LLC is pleased to announce that it has been awarded the National Institute of Health – HEAL award effective September 26, 2019.

Imbed Biosciences, Inc. announced that it has been awarded a $1.5 million two-year Small Business Innovation Research grant from the National Institute for Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Avedro, Inc. with Glaukos Corporation.

Cellular Biomedicine Group, Inc. announced that a drug application* for its off-the-shelf autologous adipose-derived mesenchymal progenitor cell ReJoin® therapy for Knee Osteoarthritis has been accepted for a Phase II clinical trial in China.

SpendEdge, a leading provider of supply market intelligence solutions, has announced the completion of their latest success story on reducing the expenditure by 23% for a medical device manufacturer by performing supply market assessment.

Mylan N.V. announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange Commission.

Incyte (Nasdaq:INCY) announces updated results, including the final result for the primary endpoint, from its Phase 2 FIGHT-202 trial evaluating pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Genentech, a member of the Roche Group, announced positive data from the Phase III IMpower110 study evaluating Tecentriq® as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations.